Juvenescence completes Series A Financing of $50 Million
We were intrigued to hear that Juvenescence Limited – a biotech company and development firm that focuses on the development of therapies aimed at aging – has raised $50 million as part of a series A funding round.
Jim Mellon said that the company’s chairman, Jim Mellon stated that \”we are thrilled with the progress that we have made, and the trust that investors have shown in us. We hope that this world-class business will be a leader in the field of longevity science, for the benefit humanity, as well as generating superb returns for shareholders.\” Our company’s ethos is to accelerate the science to add healthy years to everyone, and we are doing this at record speed.
Juvenescence, which was founded in October 2016, has now raised $63 million through international investors and is moving forward on a number key projects. The company is made up of business leaders as well as an excellent scientific team headed by Dr. Declan Doogan.
Source:
https://www.leafscience.org/juvenescence-completes-50-million-series-a-financing-round/
